Actinogen Medical Limited (ACW.AX)
- Previous Close
0.0290 - Open
0.0290 - Bid 0.0290 x 194091900
- Ask 0.0300 x 380640100
- Day's Range
0.0290 - 0.0300 - 52 Week Range
0.0150 - 0.0634 - Volume
2,674,332 - Avg. Volume
3,306,936 - Market Cap (intraday)
69.808M - Beta (5Y Monthly) 2.28
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer's disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
www.actinogen.com.auRecent News: ACW.AX
Performance Overview: ACW.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACW.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACW.AX
Valuation Measures
Market Cap
69.81M
Enterprise Value
58.38M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.83
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-4.04
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-59.24%
Return on Equity (ttm)
-106.02%
Revenue (ttm)
4.79M
Net Income Avi to Common (ttm)
-14.87M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
11.47M
Total Debt/Equity (mrq)
0.37%
Levered Free Cash Flow (ttm)
-7.09M
Company Insights: ACW.AX
ACW.AX does not have Company Insights